PURPOSE:High plasma osteopontin (OPN) levels have been reported to be an adverse prognostic factor in head and neck squamous cell carcinomas (HNSCC), correlate with tumor hypoxia, and be predictive of benefit from hypoxia-targeted therapy. We sought to confirm the prognostic and predictive significance of OPN in patients treated on a large international trial. EXPERIMENTAL DESIGN:Patients with stage III/IV HNSCC were randomized to receive definitive radiotherapy concurrently with cisplatin or cisplatin plus the hypoxic cell cytotoxin, tirapazamine (TPZ). Eligibility criteria for this prospective substudy included plasma sample availability for OPN assay by ELISA and absence of major radiation therapy deviations (N = 578). OPN concentrations were analyzed for overall survival (OS) and time to locoregional failure (TTLRF), adjusting for known prognostic factors. Additional analysis was carried out in patients with available tumor p16(INK4A) staining status. RESULTS: The median OPN level was 544 ng/mL (range: 7-2,640). High OPN levels were not associated with worse OS (relative HR, 1.03 for highest tertile) or TTLRF (relative HR 0.91 for highest tertile). There was no interaction between OPN and treatment arm for OS or TTLRF (P = 0.93 for OS; P = 0.87 for TTLRF). For the highest tertile the 2-year OS was 66% on control arm and 67% on TPZ arm (HR = 1.11, P = 0.67). Similarly for p16(INK4A) negative patients in the highest tertile, the 2-year OS was 61% on control arm and 63% on TPZ arm (HR = 1.05, P = 0.86). CONCLUSIONS: We found no evidence that high plasma OPN levels were associated with an adverse prognosis in HNSCC, or were predictive of benefit with hypoxia targeting therapy.
RCT Entities:
PURPOSE: High plasma osteopontin (OPN) levels have been reported to be an adverse prognostic factor in head and neck squamous cell carcinomas (HNSCC), correlate with tumor hypoxia, and be predictive of benefit from hypoxia-targeted therapy. We sought to confirm the prognostic and predictive significance of OPN in patients treated on a large international trial. EXPERIMENTAL DESIGN:Patients with stage III/IV HNSCC were randomized to receive definitive radiotherapy concurrently with cisplatin or cisplatin plus the hypoxic cell cytotoxin, tirapazamine (TPZ). Eligibility criteria for this prospective substudy included plasma sample availability for OPN assay by ELISA and absence of major radiation therapy deviations (N = 578). OPN concentrations were analyzed for overall survival (OS) and time to locoregional failure (TTLRF), adjusting for known prognostic factors. Additional analysis was carried out in patients with available tumorp16(INK4A) staining status. RESULTS: The median OPN level was 544 ng/mL (range: 7-2,640). High OPN levels were not associated with worse OS (relative HR, 1.03 for highest tertile) or TTLRF (relative HR 0.91 for highest tertile). There was no interaction between OPN and treatment arm for OS or TTLRF (P = 0.93 for OS; P = 0.87 for TTLRF). For the highest tertile the 2-year OS was 66% on control arm and 67% on TPZ arm (HR = 1.11, P = 0.67). Similarly for p16(INK4A) negative patients in the highest tertile, the 2-year OS was 61% on control arm and 63% on TPZ arm (HR = 1.05, P = 0.86). CONCLUSIONS: We found no evidence that high plasma OPN levels were associated with an adverse prognosis in HNSCC, or were predictive of benefit with hypoxia targeting therapy.
Authors: J Overgaard; H S Hansen; M Overgaard; L Bastholt; A Berthelsen; L Specht; B Lindeløv; K Jørgensen Journal: Radiother Oncol Date: 1998-02 Impact factor: 6.280
Authors: Kalu U E Ogbureke; Nikolaos G Nikitakis; Gary Warburton; Robert A Ord; John J Sauk; Jennifer L Waller; Larry W Fisher Journal: Oral Oncol Date: 2007-02-15 Impact factor: 5.337
Authors: Nigel Brockton; Joseph Dort; Harold Lau; Desiree Hao; Sony Brar; Alexander Klimowicz; Stephanie Petrillo; Roman Diaz; Corinne Doll; Anthony Magliocco Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-01 Impact factor: 7.038
Authors: Quynh-Thu Le; Patrick D Sutphin; Soumya Raychaudhuri; Sheue Ching T Yu; David J Terris; Ho Sheng Lin; Bert Lum; Harlan A Pinto; Albert C Koong; Amato J Giaccia Journal: Clin Cancer Res Date: 2003-01 Impact factor: 12.531
Authors: Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko Journal: Nat Rev Cancer Date: 2008-03 Impact factor: 60.716
Authors: Dirk Vordermark; Harun M Said; Astrid Katzer; Thomas Kuhnt; Gabriele Hänsgen; Jürgen Dunst; Michael Flentje; Matthias Bache Journal: BMC Cancer Date: 2006-08-15 Impact factor: 4.430
Authors: Quynh-Thu Le; Richard Fisher; Kelly S Oliner; Richard J Young; Hongbin Cao; Christina Kong; Edward Graves; Rodney J Hicks; Grant A McArthur; Lester Peters; Brian O'Sullivan; Amato Giaccia; Danny Rischin Journal: Clin Cancer Res Date: 2012-03-01 Impact factor: 12.531
Authors: Joseph C Walsh; Artem Lebedev; Edward Aten; Kathleen Madsen; Liane Marciano; Hartmuth C Kolb Journal: Antioxid Redox Signal Date: 2014-05-09 Impact factor: 8.401
Authors: Milan Grkovski; Nancy Y Lee; Heiko Schöder; Sean D Carlin; Bradley J Beattie; Nadeem Riaz; Jonathan E Leeman; Joseph A O'Donoghue; John L Humm Journal: Eur J Nucl Med Mol Imaging Date: 2017-05-24 Impact factor: 9.236